Abstracts tagged "COVID-19"

Abstract Number: 1849 • ACR Convergence 2023
Impact of the First Three Waves of the Covid-19 Pandemic on Everyday Restrictions and Clinical Care of Patients with Spondyloarthritis Across Europe – Results from the EuroSpA Collaboration
Brigitte Michelsen¹, Bente Glintborg², Kim Lauper³, Bjorn Gudbjornsson⁴, Lykke Ørnbjerg⁵, Gerdur Maria Gröndal⁶, Karin Laas⁷, Sigrid Vorobjov⁸, Dan Nordstrom⁹, Heikki Relas⁹, Adrian Ciurea¹⁰, Burkhard Moeller¹¹, Isabel Castrejon¹², Lucia Otero-Valera¹³, Ziga Rotar¹⁴, Katja Perdan Pirkmajer¹⁵, Anne Gitte Loft¹⁶, Jakub Zavada¹⁷, Karel Pavelka¹⁸, Eirik Kristianslund¹⁹, Tore Kvien²⁰, Marleen van de Sande²¹, Pasoon Hellamand²², Florenzo Iannone²³, Roberto F. Caporali²⁴, Ana Maria Rodrigues²⁵, Maria Jose Santos²⁶, Catalin Codreanu²⁷, Corina Mogosan²⁸, Merete Hetland⁵ and Mikkel Østergaard²⁹, ¹Rigshospitalet Glostrup; Diakonhjemmet Hospital; Sørlandet Hospital, Copenhagen, Denmark, ²Rigshospitalet Glostrup, University of Copenhagen, Virum, Denmark, ³Geneva University Hospitals, Genève, Switzerland, ⁴Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶Landspitali University Hospital; University of Iceland, Reykjavik, Iceland, ⁷Department of Rheumatology, East-Tallinn Central Hospital, Tallinn, Estonia, ⁸National Institute for Health Development, Tallinn, Estonia, ⁹Helsinki University Hospital, Helsinki, Finland, ¹⁰University Hospital Zurich, Zürich, Switzerland, ¹¹Inselspital - University Hospital Bern, Bern, Switzerland, ¹²Hospital Universitario Gregorio Marañón, Madrid, Spain, ¹³Spanish Society of Rheumatology, Madrid, Spain, ¹⁴University Medical Centre Ljubljana, Ljubljana, Slovenia, ¹⁵University Medical Centre Ljubljana; University of Ljubljana, Ljubljana, Slovenia, ¹⁶Aarhus University, Horsens, Denmark, ¹⁷Institute of Rheumatology; Charles University, Prague, Czech Republic, ¹⁸Institut of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Charles University, Praha, Czech Republic, ¹⁹Diakonhjemmet Hospital, Oslo, Norway, ²⁰Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ²¹Amsterdam UMC, University of Amsterdam, Department of Rheumatology & Clinical Immunology and Department of Experimental Immunology, Amsterdam Infection & Immunity Institute; Amsterdam Rheumatology & Immunology Center (ARC), Academic Medical Center, Amsterdam, Netherlands, ²²Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, Netherlands, ²³Rheumatology Unit, Department of Precision and Regenerative Medicine and Ionian Area, University of Bari "Aldo Moro", Bari, Italy, ²⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ²⁵Sociedade Portuguesa de Reumatologia; Nova Medical School; Hospital dos Lusíadas, Lisbon, Portugal, ²⁶Hospital Garcia de Orta, Almada, Lisboa, Portugal, ²⁷Center for Rheumatic Diseases, Bucharest, Romania, ²⁸University of Medicine and Pharmacy, Bucharest, Romania, ²⁹Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark
Background/Purpose: The Covid-19 pandemic constituted major challenges for health-care services worldwide. We aimed to compare Covid-19 restrictions across Europe during the first three waves of…
Abstract Number: 2478 • ACR Convergence 2023
Effect of Conventional and Biologic Disease-Modifying Anti-Rheumatic Drugs on the Antibody Response to Four Doses of COVID-19 mRNA Vaccines in Children with Autoimmune and Rheumatic Diseases
Janna Shapiro¹, Florence Choi², Amy Xu³, Trang Duong⁴, Anne-Claude Gingras⁵, Sasha Bernatsky⁶, Susanne (Susa) Benseler⁷ and Rae Yeung⁸, ¹University of Toronto, Toronto, ON, Canada, ²Hong Kong Hospital Authority, Hong Kong, Hong Kong, ³Division of Rheumatology, Department of Paediatrics, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada, ⁴The Hospital for Sick Children, Toronto, ON, Canada, ⁵Lunenfeld-Tanenbaum Research Institute at Mount Sinai Hospital Sinai Health, Toronto, ON, Canada, ⁶Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁷University of Calgary, Calgary, AB, Canada, ⁸The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada
Background/Purpose: Children with rheumatic and autoimmune diseases are often treated with conventional or biologic disease-modifying antirheumatic drugs (cDMARDs and bDMARDs) to control disease. While effective,…
Abstract Number: 0144 • ACR Convergence 2023
COVID-19 Infection in People with Immune Mediated Inflammatory Diseases Who Received SARSCo-V2 Vaccines
Tetiana Shcholok¹, Charles N Bernstein¹, Catherine Card², RuthAnn Marrie¹, Christine Mesa², John Kim² and Carol Hitchon¹, ¹University of Manitoba, Winnipeg, MB, Canada, ²Public Health Agency of Canada, Winnipeg, MB, Canada
Background/Purpose: Vaccines targeting the SARSCo-V2 virus protect against severe COVID-19 infection. Some immunosuppressive therapies impair SARSCo-V2 vaccine mediated immunogenicity and may increase the risk of…
Abstract Number: 0222 • ACR Convergence 2023
Predictors of Adverse Prognosis Following Hospitalization for COVID-19 Infection in Patients with Immune Mediated Inflammatory Diseases Treated with Rituximab
Pei-hsinq Lai¹, Ting-wei Chang², Shih-hsun Lan², Chiao-Feng Cheng², Cheng-Hsun Lu² and Song-Chou Hsieh², ¹Taipei City Hospital, Zhongxiao Branch, Taipei, Taiwan, ²National Taiwan University Hospital, Taipei, Taiwan
Background/Purpose: Rituximab (RTX) is widely used in immune mediated inflammatory disease (IMID) patients refractory to conventional treatment. Previous studies have indicated that RTX in IMID…
Abstract Number: 1065 • ACR Convergence 2023
Association Between COVID-19 and Disease-Modifying Antirheumatic Drugs
Ogheneyoma Akpoviroro¹, Nathan Sausers², Oghenetejiro Akpoviroro³, Queeneth Uwandu¹, Myriam Castagne⁴, Elga Rodrigues⁴, Lefulesele Khoalone¹, sara Humayun¹ and Jameson Woodard¹, ¹Geisinger Wyoming Valley Medical Center, Wilkes-Barre, PA, ²Pennsylvania State University, State College, PA, ³Mater Dei Hospital, Msida, Malta, ⁴Boston University, Boston, MA
Background/Purpose: Describe patients(pts) hospitalized with COVID-19C(C19) who were on disease modifying antirheumatic drugs (DMARDs) before admission(BA); assess if clinical outcomes differed from pts without BA…
Abstract Number: 1673 • ACR Convergence 2023
Immunomodulatory Treatment and Autoimmune Patient Responses to COVID-19 Booster Shots: Results from the Covid-19 VaccinE Response in Rheumatology Patients (COVER) Study
Amy S. Mudano¹, Gary Cutter², Ted R Mikuls³, Geoffrey Thiele⁴, Emily Holladay², Kevin Withrop⁵, Mark Law⁴, Bart Hamilton⁴, Monique Bastidas⁶, Michael Zikry⁶, Kelly Chun⁶, Michael George⁷ and Jeffrey Curtis², ¹Illumination Health, Hoover, AL, ²University of Alabama at Birmingham, Birmingham, AL, ³Division of Rheumatology and Immunology, University of Nebraska Medical Center, Omaha, NE, ⁴University of Nebraska Medical Center, Omaha, NE, ⁵Oregon Health & Science University, Schools of Medicine and Public Health,, Portland, OR, ⁶Labcorp, Calabasas, CA, ⁷University of Pennsylvania, Philadelphia, PA
Background/Purpose: Given an increased risk of COVID-19 in patients with autoimmune conditions, we must better understand the immunogenicity and safety of SARS-CoV-2 vaccines in people…
Abstract Number: 1928 • ACR Convergence 2023
Response to Sars-Cov2 Vaccination in Rheumatic and Neurological Patients Treated with Different Immunosuppressive Therapies
Cristina Calomarde Gomez¹, Raquel Ugena García¹, Julia Valera², Melisa Mena², Maria Esteve², Irma Casas², jose Antonio Dominguez-Benitez², lidia Carabias-Ane², isaac Nuño-Ruiz², Cristina ramo-Tello², Javier Santesmases², Lourdes Mateo Soria³ and Melania Martinez Morillo¹, ¹Rheumatology department. Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ³HOSPITAL GERMANS TRIAS I PUJOL, Badalona, Spain
Background/Purpose: Vaccination against SARS-CoV2 has been the primary global strategy to prevent severe forms of this respiratory infection. However, multiple studies have shown that patients…
Abstract Number: 2511 • ACR Convergence 2023
Superior SARS-CoV-2 Antibody Response Achieved in Rituximab-treated Patients When Vaccinated Against COVID-19 Before Compared to After Rituximab Initiation – Guidance for Future Vaccination Strategies
Christian Ammitzbøll¹, Marianne Kragh Thomsen², Lars Erik Bartels¹, Marie-Louise From Hermansen¹, Mathias Hänel³, Rasmus Klose-Jensen¹, Mads Christian Lamm Larsen¹, Cecile Bo Hansen⁴, Morgan Oliver Lauritsen¹, Susan Mikkelsen⁵, Clara Mistegaard¹, Morten Aagaard Nielsen¹, Esben Naeser¹, Janne Bille Mønster Olesen⁵, Peter Garred⁴, Christian Erikstrup⁵, Ellen-Margrethe Hauge⁶ and Anne Troldborg⁶, ¹Rheumatology, Aarhus University Hospital, Aarhus, Denmark, ²Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark, ³Rheumatollogy, Aarhus University Hospital, Aarhus, Denmark, ⁴Clinical Immunology, sect. 7631, Rigshospitalet, Copenhagen, Denmark, ⁵Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark, ⁶Aarhus University Hospital, Aarhus, Denmark
Background/Purpose: Rituximab (RTX) treatment significantly decreases the antibody response to COVID-19 vaccines, raising concerns about its use. However, unlike during the pandemic, most patients initiating…
Abstract Number: 0152 • ACR Convergence 2023
Long Covid in Persons with Self-Reported Arthritis – Symptoms, Associated Factors and Functional Limitations
Debbie Ehrmann Feldman¹ and Barbara Mazer², ¹Université de Montréal, Montreal, QC, Canada, ²McGill University, Montreal, QC, Canada
Background/Purpose: Long covid, a condition whereby signs and symptoms post covid-19 infection continue for more than 12 weeks and are not explained by an alternative…
Abstract Number: 0223 • ACR Convergence 2023
Severity and Risk Factors of Hospitalization of Omicron in Patients with Rheumatoid Arthritis
Yan Wang¹, mengyao zhang², Sitian Zang¹, liang luo³, Chun Li¹, Jing He¹ and zhanguo li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University People's Hospital, Beijing, China, ³Department of Chinese Medicine, the People's Hospital of Yubei District of Chongqing City, Chongqing, China; Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Background/Purpose: There is still lack of data on the prognosis of patients with RA who have been infected with SARS-Cov-2 Omicron variant, a new strain…
Abstract Number: 1093 • ACR Convergence 2023
Development of Adaptive Immunity Against Different SARS-CoV-2 Variants over the Course of Three COVID-19 Vaccinations in Patients with Inflammatory Rheumatic Diseases
Liam Huppke¹, Paul Wratil², Marie Bischof², Stefan Wolfrum¹, Fabian Ullrich¹, Delila Singh¹, Julia Lichtnekert¹, Lea Grümme¹, Christina Gebhardt¹, Klaus Krüger³, Franziska Wiesent⁴, Alla Skapenko¹, Oliver Keppler⁵ and Hendrik Schulze-Koops⁶, ¹Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, University of Munich, Munich, Germany, ²Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU Munich, Munich, Germany, ³Praxiszentrum St. Bonifatius, Munich, Germany, ⁴Endokrinologikum München, Munich, Germany, ⁵Max von Pettenkofer Institute & Gene Centre, Virology, National Reference Centre for Retroviruses, LMU München, Munich, Germany, ⁶Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians–University Munich, Munich, Germany
Background/Purpose: Even though individuals with inflammatory rheumatic diseases (IRDs) were excluded from the SARS-CoV-2 vaccine trails, studies have shown that these individuals at risk of…
Abstract Number: 1677 • ACR Convergence 2023
Two-week Break in Methotrexate Treatment and COVID-19 Vaccine Response. Results of the Vaccine Response on off Methotrexate (VROOM) Study, an Open Label, Prospective, Two-arm Parallel-group, Multi-center, Superiority, Randomized Controlled Trial
Abhishek Abhishek¹, Nicholas Peckham², Corinna Pade³, Joseph Gibbons³, Lucy Cureton², Anne Francis², Vicki Barber², Jennifer Williams², duncan Appelbe², lucy Eldridge², patrick Julier², daniel Altmann⁴, James Bluett⁵, Tim Brooks⁶, Laura Coates², ines Rombach⁷, Amanda Semper⁶, Ashley Otter⁶, Ana Valdes¹, Jonathan Nguyen-Van-Tam¹, Hywel Williams¹, Aine McKnight³, Rosemary Boyton⁴ and jonathan Cook², ¹University of Nottingham, Nottingham, United Kingdom, ²University of Oxford, Oxford, United Kingdom, ³Queen Mary University of London, London, United Kingdom, ⁴Imperial College London, London, United Kingdom, ⁵University of Manchester, Manchester, United Kingdom, ⁶UK Health Security Agency, Porton Down, United Kingdom, ⁷University of Sheffield, Sheffield, United Kingdom
Background/Purpose: Immunosuppressive treatments inhibit vaccine-induced immunity. We evaluated if a two-week interruption of methotrexate treatment immediately after COVID-19 booster improved antibody response against spike protein…
Abstract Number: 1935 • ACR Convergence 2023
Pre-exposure Prophylaxis with Tixegvimab/cilgavimab Is Effective in Limiting the Risk and Severity of COVID-19 in Patients with Auto Immune or Inflammatory Diseases at Increased Risk of Severe COVID-19
Marion THOMAS¹, Maeva MASSON², Raphaele Seror³, Samuel Bitoun⁴, Henry DUPUY⁵, Lazato ESTIBALIZ⁵, Christophe Richez⁶, Yannick ALLANORE⁷ and Jerome AVOUAC⁸, ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²CHU Toulouse, Toulouse, France, ³University Hospital Paris Saclay, Le Kremlin-Bicêtre, France, ⁴CHU Bicêtre APHP, Le Kremlin-Bicêtre, France, ⁵CHU Bordeaux, Bordeaux, France, ⁶Université de Bordeaux, Bordeaux, France, ⁷Université Paris Cité, Paris, France, ⁸Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France
Background/Purpose: Patients with autoimmune or inflammatory diseases treated with immunosuppressants such as anti-CD20 are at increased risk for severe COVID-19 and have a high probability…
Abstract Number: 2536 • ACR Convergence 2023
DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection
Tanya Selvam, Kelli Peterman, Arezoo Haghshenas and Lucy Liu, Kaiser Permanente Northern California, Oakland, CA
Background/Purpose: The COVID-19 pandemic affected medication adherence in patients with autoimmune disease (AD) due to their fear of contracting COVID-19, financial hardship, and medication shortage.…
Abstract Number: 0202 • ACR Convergence 2023
Analysis of the Effects of Immunosuppressive Therapy on Herpes Zoster Events After Each of Three Doses of the BNT162b2 mRNA Vaccine in Patients with Spondyloarthritis (SpA)
Tal Gazitt¹, Noa Hayat², Amir Haddad², Joy Feld³, Nili Stein², Idit Lavi², Ilan Feldhamer⁴, Arnon Dov Cohen⁵, Walid Saliba² and Devy Zisman², ¹Carmel Hospital, Haifa, Israel, ²Carmel Medical Center, Haifa, Israel, ³Carmel and Zvulun Medical Centre, Haifa, Israel, ⁴Chief Physician's Office, Clalit Health Services, Tel Aviv, Israel, ⁵Ben-Gurion University of the Negev, Beer-Sheva, Israel
Background/Purpose: The importance and efficacy of mRNA COVID-19 vaccination in coping with the pandemic are well established, but inconsistencies remain in the data regarding side…

« Previous Page
1
…
6
7
8
9
10
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].